drugset / Trial / NCT05564052
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to provide continued access to treatment for participants who continue to benefit from treatment.
Timeline
- Start
- 2022-12-06
- Primary completion
- 2023-12-06
- Completion
- 2024-09-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Subject | Ibrutinib | Small molecule | 140 mg | Oral |
| Subject | Ibrutinib | Small molecule | 420 mg | Oral |
| Subject | Ibrutinib | Small molecule | 560 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 20 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |